There is a considerable amount of evidence that supports the possibility of an increased risk
of pneumonia associated with prolonged use of inhaled corticosteroids (ICS) in patients with …

Introduction: Inhaled corticosteroids (ICS) are known to increase the risk of pneumonia in
patients with chronic obstructive pulmonary disease. To estimate the association between …

Recently it has been suggested that there is a causal association between the use of
inhaled corticosteroids (ICSs) and the risk of developing pneumonia in patients with chronic …

Background Inhaled corticosteroids (ICS) are known to increase the risk of pneumonia in
patients with chronic obstructive pulmonary disease (COPD). It is unclear whether the risk of …

Background: Inhaled corticosteroids are commonly prescribed for patients with severe
COPD. They have been associated with increased risk of pneumonia but not with increased …

Background The benefit harm profile of inhaled corticosteroids, and their effect on patient
oriented outcomes and comorbid pneumonia, osteoporosis and cardiovascular disease in …

Inhaled corticosteroids (ICS), commonly used to treat chronic obstructive pulmonary disease
(COPD), have been associated with an increased risk of pneumonia in randomised trials …

Background Use of inhaled corticosteroids (ICS) increases the risk of pneumonia in chronic
obstructive pulmonary disease (COPD), but the magnitude of risk with different ICS remains …

Corticosteroids are frequently prescribed anti-inflammatory medications. Inhaled
corticosteroids (ICS) are indicated for Chronic Obstructive Pulmonary Disease (COPD) and …

ICS are anti-inflammatory agents which have been suggested to benefit people with
worsening symptoms of COPD, by improving lung function, reducing exacerbation of …